On 13 November 2018, Van Bael & Bellis co-managing partner Jean-François Bellis moderated a panel at LeadershIP EU’s 2nd annual conference, which explored the impact of IP and competition policy on global business and innovation looking toward the future, 5G and emerging technologies. The panel was titled Effects-Based Analysis: Where Do We Stand on Both Sides of the Atlantic? and the discussion focused on the competition law trends in the US and the EU in the area of effects-based analysis. The other panel members were the Honourable Douglas Ginsburg, Senior Circuit Judge, US Court of Appeals for the District of Columbia and Sir Robin Jacob, Sir Hugh Laddie Chair of Intellectual Property Law, University College London and Former Justice in the Court of Appeal of England and Wales. Further details about the conference are available here.

On 2 October 2018, Van Bael & Bellis partner Catherine Longeval spoke on the subject of “Recent Developments in Life Sciences in the EU - Regulatory” at a conference in Zürich organized by the Europa Institut of Zürich University. Catherine also participated in a round table on “M&A transactions in the life sciences sector”. Other members of the round table were Michael Pitzner (Senior Legal Counsel, Novartis), Markus Wang (Bär & Karrer) and Franz Schubiger (Partner, Pestalozzi).

Regulatory

Get in touch

Please fill out the form below along with your query and someone from the team will get back to you. Alternatively you can email [email protected]

First Name *

Last Name *

Email *

Company

Message

Thank you. Your message has been sent to Van Bael & Bellis.

Recommendations

The quality of the advice is great - we have been asking some complex questions and they have given clear and to-the-point advice and have been very proactive in providing alternative solutions.

Chambers Europe

Van Bael & Bellis has ‘impressive knowledge of dispute resolution, including mediation’. The firm is notable for its strong regulatory and administrative law contentious practice as well as its impressive life sciences sector presence.

Legal 500

They patiently try to understand the mentality of people in different cultures and pay full respect to that. This attitude is rare in a highly expert world. We are fully satisfied with their practice and the results therefrom.

IFLR1000

They are very responsive, and experienced in pharma and compliance-related matters. They always indicate the timelines of the work they do and keep the client informed on the status of the work.

Chambers Europe

Team focus

Van Bael & Bellis is well known for its client-centred approach, commitment to excellence, exceptional client service and personalised attention.

The Chair of the Health and Social Care Committee of the UK House of Commons wrote on 7 November 2018 to Vertex, the National Health Service (“NHS England”) and the National Institute for Health and Care Excellence (“NICE”) to request pricing information regarding the cystic fibrosis medicine Orkambi® (see attached letters). The move follows two-and-a-half years of unsuccessful pricing negotiations between these parties.

The Royal Decree of 30 July 2018 (the Royal Decree), which entered into force on 31 October 2018, sets out the legal framework in relation to the new central register of beneficial ownership (the UBO Register) and the obligation for all Belgian companies and other entities to communicate information in relation to their ultimate beneficial owner(s) (UBOs) for inclusion in the UBO Register.